Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis

Pharmacological Research

Volumn 105, Issue , 2016, Pages 198-209

  Sahebkar, Amirhossein ^a,b   Simental Mendía, Luis E ^c   Stefanutti, Claudia ^d   Pirro, Matteo ^e  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d POLICLINICO UMBERTO I   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Coenzyme Q10; Lipids; Lipoprotein(a); Nutraceuticals

Indexed keywords

CHOLESTEROL; LIPOPROTEIN A; TRIACYLGLYCEROL; UBIDECARENONE; LIPID; UBIQUINONE;

CHOLESTEROL BLOOD LEVEL; DIET SUPPLEMENTATION; HUMAN; META ANALYSIS; NUTRITIONAL ASSESSMENT; NUTRITIONAL VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REVIEW; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; ANALYSIS; BLOOD; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENT; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; HUMANS; LIPIDS; LIPOPROTEIN(A); RISK FACTORS; UBIQUINONE;

EID: 84957578017     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.01.030     Document Type: Article

References (48)

1. F. Kronenberg, and G. Utermann Lipoprotein(a): resurrected by genetics J. Intern. Med. 273 2013 6 30
2. P.R. Kamstrup, A. Tybjaerg-Hansen, R. Steffensen, and B.G. Nordestgaard Genetically elevated lipoprotein(a) and increased risk of myocardial infarction JAMA 301 2009 2331 2339
3. S. Lamon-Fava, S.M. Marcovina, J.J. Albers, H. Kennedy, C. Deluca, C.C. White, L.A. Cupples, J.R. McNamara, L.J. Seman, V. Bongard, and E.J. Schaefer Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring study J. Lipid Res. 52 2011 1181 1187
4. Emerging Risk Factors Collaboration, E. Di Angelantonio, P. Gao, L. Pennells, S. Kaptoge, M. Caslake, A. Thompson, A.S. Butterworth, N. Sarwar, D. Wormser, D. Saleheen, C.M. Ballantyne, B.M. Psaty, J. Sundström, P.M. Ridker, D. Nagel, R.F. Gillum, I. Ford, P. Ducimetiere, S. Kiechl, W. Koenig, R.P. Dullaart, G. Assmann, R.B. D'Agostino Sr., G.R. Dagenais, J.A. Cooper, D. Kromhout, A. Onat, R.W. Tipping, A. Gómez-de-la-Cámara, A. Rosengren, S.E. Sutherland, J. Gallacher, F.G. Fowkes, E. Casiglia, A. Hofman, V. Salomaa, E. Barrett-Connor, R. Clarke, E. Brunner, J.W. Jukema, L.A. Simons, M. Sandhu, N.J. Wareham, K.T. Khaw, J. Kauhanen, J.T. Salonen, W.J. Howard, B.G. Nordestgaard, A.M. Wood, S.G. Thompson, S.M. Boekholdt, N. Sattar, C. Packard, V. Gudnason, and J. Danesh Lipid-related markers and cardiovascular disease prediction JAMA 307 2012 2499 2506
5. B. Cantin, F. Gagnon, S. Moorjani, J.P. Després, B. Lamarche, P.J. Lupien, and G.R. Dagenais Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The quebec cardiovascular study J. Am. Coll. Cardiol. 31 1998 519 525
6. S. Erqou, S. Kaptoge, P.L. Perry, A.E. Di, A. Thompson, I.R. White, S.M. Marcovina, R. Collins, S.G. Thompson, and J. Danesh Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JAMA 302 2009 412 423
7. S. Lamon-Fava, M.R. Diffenderfer, and S.M. Marcovina Lipoprotein(a) metabolism Curr. Opin. Lipidol. 25 2014 189 193
8. B. Kolski, and S. Tsimikas Emerging therapeutic agents to lower lipoprotein(a) levels Curr. Opin. Lipidol. 23 2012 560 568
9. F.J. Raal, R.P. Giugliano, M.S. Sabatine, M.J. Koren, G. Langslet, H. Bays, D. Blom, M. Eriksson, R. Dent, S.M. Wasserman, F. Huang, A. Xue, M. Albizem, R. Scott, and E.A. Stein Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials J. Am. Coll. Cardiol. 63 2014 1278 1288
10. C. Stefanutti, G. D'Alessandri, G. Russi, G. De Silvestro, M.G. Zenti, P. Marson, D. Belotherkovsky, A. Vivenzio, and S. Di Giacomo Treatment of symptomatic HyperLp(a) lipoproteinemia with LDL-apheresis: a multicentre study Atheroscler. Suppl. 10 2009 89 94
11. C. Stefanutti, and U. Julius Lipoprotein apheresis: state of the art and novelties Atheroscler. Suppl. 14 2013 19 27
12. M.V. Ezhov, M.S. Safarova, O.I. Afanasieva, O.A. Pogorelova, M.I. Tripoten, I.Y. Adamova, G.A. Konovalov, T.V. Balakhonova, and S.N. Pokrovsky Specific lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels Atheroscler. Suppl. 18 2015 163 169
13. M.S. Safarova, M.V. Ezhov, O.I. Afanasieva, Y.G. Matchin, R.V. Atanesyan, I.Y. Adamova, E.A. Utkina, G.A. Konovalov, and S.N. Pokrovsky Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography Atheroscler. Suppl. 14 2013 93 99
14. B.G. Nordestgaard, M.J. Chapman, K. Ray, J. Borén, F. Andreotti, G.F. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O.S. Descamps, E. Fisher, P.T. Kovanen, J.A. Kuivenhoven, P. Lesnik, L. Masana, Z. Reiner, M.R. Taskinen, L. Tokgözoglu, and A. Tybjærg-Hansen European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status Eur. Heart J. 31 2010 2844 2853
15. European Association for Cardiovascular Prevention & Rehabilitation, Z. Reiner, A.L. Catapano, G. De Backer, I. Graham, M.R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M.J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P.P. Filardi, G. Riccardi, R.F. Storey, D. Wood, and ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur. Heart J. 32 2011 1769 1818
16. L. Ernster, and G. Dallner Biochemical, physiological and medical aspects of ubiquinone function Biochim. Biophys. Acta 1271 1995 195 204
17. 10 in patients with coronary artery disease: discovery of a new role Int. J. Cardiol. 68 1999 23 29
18. A.F. Cicero, G. Derosa, A. Miconi, L. Laghi, S. Nascetti, and A. Gaddi Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates Biomed. Pharmacother. 59 2005 312 317
19. 10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy Iran J. Kidney Dis. 5 2011 114 118
20. 10 as adjuvant therapy in patients with type 2 diabetes mellitus Am. J. Pharm. Sci. 2 2014 82 86
21. 10 on arterial stiffness, metabolic parameters, and fatigue in obese subjects: a double-blind randomized controlled study J. Med. Food 14 2011 386 390
22. 10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: a randomized controlled trial Atherosclerosis 216 2011 395 401
23. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, and PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 2009 b2535
24. J.P.T. Higgins, and S. Green Cochrane Handbook for Systematic Reviews of Interventions 2009 The Cochrane Collaboration London (version 5.0.2)
25. M. Borenstein, L. Hedges, J. Higgins, and H. Rothstein Comprehensive Meta-Analysis 2005 Biostat Englewood, NJ (version 2)
26. A.J. Sutton, K.R. Abrams, D.R. Jones, and et al. Methods for Meta-Analysis in Medical Research 2000 Wiley London
27. 10 concentrations - a systematic review and meta-analysis of placebo-controlled trials Pharmacol. Res. 99 2015 329 336
28. A. Sahebkar Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis Phytother. Res. 28 2014 633 642
29. G. Ferretti, T. Bacchetti, and A. Sahebkar Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials Prog. Lipid Res. 60 2015 50 73
30. S. Duval, and R. Tweedie Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis Biometrics 56 2000 455 463
31. O. Guardamagna, F. Abello, G. Anfossi, and M. Pirro Lipoprotein(a) and family history of cardiovascular disease in children with familial dyslipidemias J. Pediatr. 159 2011 314 319
32. 10: absorption, tissue uptake, metabolism and pharmacokinetics Free Radic. Res. 40 2006 445 453
33. 10 formulations Mitochondrion 7 Suppl 2007 S78 S88
34. X.P. Yang, M.J. Amar, B. Vaisman, A.V. Bocharov, T.G. Vishnyakova, L.A. Freeman, R.J. Kurlander, A.P. Patterson, L.C. Becker, and A.T. Remaley Scavenger receptor-BI is a receptor for lipoprotein(a) J. Lipid Res. 54 2013 2450 2457
35. S. Maeda, A. Abe, M. Seishima, K. Makino, A. Noma, and M. Kawade Transient changes of serum lipoprotein(a) as an acute phase protein Atherosclerosis 78 1989 145 150
36. I. Missala, U. Kassner, and E. Steinhagen-Thiessen A systematic literature review of the association of lipoprotein(a) and autoimmune diseases and atherosclerosis Int. J. Rheumatol. 2012 2012 480784
37. O. Schultz, F. Oberhauser, J. Saech, A. Rubbert-Roth, M. Hahn, W. Krone, and M. Laudes Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein(a) levels in human subjects with rheumatoid diseases PLoS One 5 2010 e14328
38. N. Müller, D.M. Schulte, K. Türk, S. Freitag-Wolf, J. Hampe, R. Zeuner, J.O. Schröder, I. Gouni-Berthold, H.K. Berthold, W. Krone, S. Rose-John, S. Schreiber, and M. Laudes IL-6 blockade by monoclonal antibodies inhibits apolipoprotein(a) expression and lipoprotein(a) synthesis in humans J. Lipid Res. 56 2015 1034 1042
39. 10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial Nutr. J. 12 2013 142
40. 10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease Nutrition 28 2012 767 772
41. 10 supplementation on metabolic profile in diabetes: a systematic review and meta-analysis J. Clin. Pharm. Ther. 40 2015 413 418
42. 10 supplementation for the primary prevention of cardiovascular disease Cochrane Database Syst. Rev. 12 2014 CD010405
43. 10 in the diet-daily intake and relative bioavailability Mol. Aspects Med. 18 Suppl 1997 S251 S254
44. 10: absorption, antioxidative properties, determinants, and plasma levels Free Radic. Res. 36 2002 389 397
45. P.N. Durrington, J.D. Schofield, T. Siahmansur, and H. Soran Lipoprotein(a): gene genie Curr. Opin. Lipidol. 25 2014 289 296
46. M. Banach, W.S. Aronow, C. Serban, A. Sahabkar, J. Rysz, L. Voroneanu, and A. Covic Lipids, blood pressure and kidney update 2014 Pharmacol. Res. 95-96 2015 111 125
47. A. Sahebkar, and G.F. Watts New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect Cardiovasc. Drugs Ther. 27 2013 559 567
48. A. Sahebkar, G.T. Chew, and G.F. Watts New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease Expert Opin. Pharmacother. 15 2014 493 503